Sunday, 5 November 2017

Novartis seeks European approval of cell therapy Kymriah

ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday it submitted an application for its cell therapy Kymriah to be approved in Europe for two forms of blood cancer.


No comments:

Post a Comment